Data presented at the American Society of Clinical Oncology annual meeting found non-White patients are less likely to receive immunotherapy for head and neck cancer, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.
Data presented at the American Society of Clinical Oncology (ASCO) annual meeting found non-White patients are less likely to receive immunotherapy for head and neck cancer, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.
Transcript
Research presented at the annual meeting of ASCO used Navigating Cancer's data to evaluate the clinical and non-clinical factors associated with immunotherapy. What were some of those key findings?
In that study, we specifically looked at a head and neck cancer patient population, those that are in the Medicare population, specifically, over the age of 65. And what we found was that beyond kind of the normal clinical drivers for utilization, there was a significant difference in terms of race and ethnicity. Patients that were White were much more likely to receive immunotherapy than their non-White counterparts in that study.
Knowing there are factors associated with being more likely to receive immunotherapy, what are some changes that can be made in how care is delivered?
I think that we need to try to remove as many barriers as possible for these patients. Today, we know that there are a lot of social determinants of health that might inhibit access to immunotherapy treatment. At Navigating Cancer, we're trying to address this by screening patients for the other aspects of their life that might impact their ability to receive immunotherapy, such as financial toxicity, mental health screenings, transportation issues.
And then I think the other thing too, is that health literacy is quite important here, as well. So, patients need to be educated around why these treatments are being prescribed to them, what the utility is of them, and how it's beneficial for their care. We provide a lot of digital education materials through our platform that are very timely and personalized to the patient so that we can start to break down that barrier of health literacy, as well.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More